半剂量钆匹醇与全剂量钆布醇用于对比增强体部MRI的疗效与安全性比较
这项随机、双盲、交叉3期研究在11国33中心纳入273例体部局灶性病变疑诊患者,比较钆匹醇0.05 mmol/kg与钆布醇0.1 mmol/kg的病灶可视化效果。结果显示钆匹醇在所有定性可视化参数上非劣于钆布醇(差值95%CI下限至少-0.10,高于非劣效界值-0.35,P<.001),不良事件频率相似。
要点
- 钆匹醇0.05 mmol/kg在体部MRI病灶可视化上非劣于钆布醇0.1 mmol/kg。
- 75%-83%的参与者中阅片者对两种对比剂增强图像无偏好。
- 两组不良事件频率、强度、类型及与对比剂注射的关联性无差异。
核心结论
- 钆匹醇0.05 mmol/kg在对比增强体部MRI病灶评估中与钆布醇0.1 mmol/kg相当,且安全性特征相似。
研究设计与样本
- 随机、双盲、交叉3期研究,2019年8月至2020年12月在11国33中心开展,273例参与者(平均年龄57岁±13[SD],162例女性)接受两种对比剂增强MRI,260例无重大方案偏离者纳入非劣效性分析;每个体部区域由三名盲法专家阅片者评估,另有三名盲法阅片者评估偏好。
关键影像表现/征象
- 阅片者评估病灶边界勾画、内部形态特征和视觉对比增强三项定性可视化参数。
- 钆匹醇在所有定性可视化参数和所有阅片者中均非劣于钆布醇(差值95%CI下限至少-0.10,高于非劣效界值-0.35,P<.001)。
- 75%-83%(206-228/276)的参与者中,阅片者对钆匹醇与钆布醇增强图像无偏好。
诊断标准与关键数值
- 非劣效性界值为-0.35,钆匹醇与钆布醇差值95%CI下限至少-0.10,高于该界值(P<.001)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Background Gadopiclenol is a macrocyclic gadolinium-based contrast agent (GBCA) with higher relaxivity compared with standard GBCAs, potentially allowing gadolinium dose reduction without decreasing efficacy. Purpose To investigate whether gadopiclenol at 0.05 mmol/kg is noninferior to gadobutrol at 0.1 mmol/kg for lesion visualization in body MRI. Materials and Methods A randomized, double-blind, crossover, phase 3 study was conducted between August 2019 and December 2020 at 33 centers in 11 countries. Adults with at least one suspected focal lesion in one of three different body regions (head and neck; breast, thorax, abdomen, or pelvis; or musculoskeletal system) underwent two contrast-enhanced MRI examinations, randomized to start with either gadopiclenol or gadobutrol. MRI examinations were read by three blinded expert readers for each respective body region. Readers rated border delineation, internal morphologic characteristics, and visual contrast enhancement. Three additional blinded readers assessed reader preference. For safety analysis, adverse events were recorded. The differences between gadopiclenol- and gadobutrol-enhanced MRI in terms of lesion visualization were analyzed with a generalized linear mixed model using a two-sided paired t test. Results Among 273 participants (mean age, 57 years ± 13 [SD]; 162 women) who underwent both gadopiclenol- and gadobutrol-enhanced MRI and had at least one correlating lesion, 260 participants without major protocol deviations were analyzed for noninferiority. Gadopiclenol was noninferior to gadobutrol for all qualitative visualization parameters and for all readers (lower limit 95% CI of the difference of at least -0.10, which was above the noninferiority margin [-0.35]; P < .001). For most participants (75%-83% [206-228 of 276]), readers reported no preference between gadopiclenol- and gadobutrol-enhanced images. Adverse events did not differ in frequency, intensity, type, or association with GBCA injection (12 of 288 participants receiving gadopiclenol and 16 of 290 receiving gadobutrol). Conclusion Gadopiclenol at 0.05 mmol/kg was comparable with gadobutrol at 0.1 mmol/kg for lesion evaluation at contrast-enhanced body MRI and had a similar safety profile. Clinical trial registration no. NCT03986138 Published under a CC BY 4.0 license. Supplemental material is available for this article. See also the editorial by Bashir and Thomas in this issue.
引用
- Kuhl C, Csőszi T, Piskorski W, et al. Efficacy and Safety of Half-Dose Gadopiclenol versus Full-Dose Gadobutrol for Contrast-enhanced Body MRI. Radiology. 2023. PMID: 37462494. doi:10.1148/radiol.222612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。